StimAire has invented a revolutionary neuromodulation platform that can be injected through a needle in a doctor’s office in under 15 minutes.

Our first clinical target is obstructive sleep apnea which is a $30 billion market worldwide. Our device eliminates major surgery and a hospital stay, creating a patient-friendly solution for healthy sleep. The first human clinical trial with our ground-breaking device will begin in 2022.

StimAire has a rich intellectual property portfolio that only begins with this first application. Our platform has the potential to treat bladder urgency, gastrointestinal diseases, autoimmune disorders, depression, pain, cluster headaches and more.

StimAire is a venture-backed company.